SCHEMBL446303

SCHEMBL446303

CC1(C)Cc2ccc(Br)cc2C(=O)C1(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
BRD4 O60885 1/20 0.40
BACE1 P56817 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
TDP2 O95551 1/20 0.38
PARP1 P09874 1/20 0.38
PARP10 Q53GL7 1/20 0.38
TGM2 P21980 1/20 0.38
CES1 P23141 1/20 0.38
CMA1 P23946 1/20 0.37
AHR P35869 1/20 0.37
S100A4 P26447 1/20 0.36
METAP1 P53582 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572850 0.80 TDP1 (0.46) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL30676574 0.80 TDP1 (0.46) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL29237810 0.77 TDP1 (0.44) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL30726 0.73 BACE1 (0.43) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL29237761 0.73 TDP1 (0.41) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL29237762 0.73 TDP1 (0.41) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL9948162 0.73 TDP1 (0.46) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL7890030 0.72 L3MBTL1 (0.42) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL427867 0.71 ALDH1A1 (0.44) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL9947977 0.71 CA1 (0.42) TDP1L3MBTL1MEN1KMT2ABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES APP, BACE1, PSEN1 TDP1 200/4885L3MBTL1 4213/4885MEN1 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.